WO2005051361A1 - Colonic purgative composition with soluble binding agent - Google Patents
Colonic purgative composition with soluble binding agent Download PDFInfo
- Publication number
- WO2005051361A1 WO2005051361A1 PCT/US2004/038220 US2004038220W WO2005051361A1 WO 2005051361 A1 WO2005051361 A1 WO 2005051361A1 US 2004038220 W US2004038220 W US 2004038220W WO 2005051361 A1 WO2005051361 A1 WO 2005051361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- purgative
- colonic
- colon
- patient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 172
- 239000008141 laxative Substances 0.000 title claims abstract description 154
- 230000001543 purgative effect Effects 0.000 title claims abstract description 145
- 230000000112 colonic effect Effects 0.000 title claims abstract description 90
- 239000011230 binding agent Substances 0.000 title claims abstract description 49
- 238000009472 formulation Methods 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 52
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 23
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 23
- 206010010774 Constipation Diseases 0.000 claims abstract description 17
- 230000008030 elimination Effects 0.000 claims abstract description 13
- 238000003379 elimination reaction Methods 0.000 claims abstract description 13
- 239000007909 solid dosage form Substances 0.000 claims abstract description 13
- 238000001356 surgical procedure Methods 0.000 claims abstract description 10
- 230000002475 laxative effect Effects 0.000 claims abstract description 8
- 210000001072 colon Anatomy 0.000 claims description 62
- 239000003826 tablet Substances 0.000 claims description 44
- 230000003204 osmotic effect Effects 0.000 claims description 35
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 33
- 239000001488 sodium phosphate Substances 0.000 claims description 28
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 28
- 235000011008 sodium phosphates Nutrition 0.000 claims description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 15
- -1 rhein Chemical compound 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 238000010926 purge Methods 0.000 claims description 11
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 10
- 210000003608 fece Anatomy 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 claims description 8
- 229960000503 bisacodyl Drugs 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 claims description 6
- 238000002483 medication Methods 0.000 claims description 6
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 5
- 239000012188 paraffin wax Substances 0.000 claims description 5
- 210000000664 rectum Anatomy 0.000 claims description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 244000134552 Plantago ovata Species 0.000 claims description 4
- 235000003421 Plantago ovata Nutrition 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 4
- 235000011152 sodium sulphate Nutrition 0.000 claims description 4
- CPUHNROBVJNNPW-VVBPCJSVSA-N (10r)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2r,3r,4r,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-10h-anthracen-9-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-VVBPCJSVSA-N 0.000 claims description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 claims description 3
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 claims description 3
- IPQVTOJGNYVQEO-UHFFFAOYSA-N 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical class OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2C1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(OC3C(C(O)C(O)C(CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-UHFFFAOYSA-N 0.000 claims description 3
- 241001116389 Aloe Species 0.000 claims description 3
- 239000010369 Cascara Substances 0.000 claims description 3
- 241000556215 Frangula purshiana Species 0.000 claims description 3
- UJIDKYTZIQTXPM-UHFFFAOYSA-N [4-[pyridin-2-yl-(4-sulfooxyphenyl)methyl]phenyl] hydrogen sulfate Chemical compound C1=CC(OS(=O)(=O)O)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS(O)(=O)=O)C=C1 UJIDKYTZIQTXPM-UHFFFAOYSA-N 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- 230000036772 blood pressure Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229940071711 casanthranol Drugs 0.000 claims description 3
- 229940058505 cascara Drugs 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 229960001777 castor oil Drugs 0.000 claims description 3
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 3
- 229960005132 cisapride Drugs 0.000 claims description 3
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 3
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229960001577 dantron Drugs 0.000 claims description 3
- 229960002997 dehydrocholic acid Drugs 0.000 claims description 3
- 229940018602 docusate Drugs 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 3
- 239000000347 magnesium hydroxide Substances 0.000 claims description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 3
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 3
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 3
- 239000004137 magnesium phosphate Substances 0.000 claims description 3
- 229960002261 magnesium phosphate Drugs 0.000 claims description 3
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 229960005249 misoprostol Drugs 0.000 claims description 3
- OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 claims description 3
- 229960005382 phenolphthalein Drugs 0.000 claims description 3
- 229930186851 sennoside Natural products 0.000 claims description 3
- 229960005077 sodium picosulfate Drugs 0.000 claims description 3
- GOZDTZWAMGHLDY-UHFFFAOYSA-L sodium picosulfate Chemical compound [Na+].[Na+].C1=CC(OS(=O)(=O)[O-])=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS([O-])(=O)=O)C=C1 GOZDTZWAMGHLDY-UHFFFAOYSA-L 0.000 claims description 3
- 239000008143 stimulant laxative Substances 0.000 claims description 3
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims description 3
- 229960002876 tegaserod Drugs 0.000 claims description 3
- 229940001496 tribasic sodium phosphate Drugs 0.000 claims description 3
- 206010002153 Anal fissure Diseases 0.000 claims description 2
- 208000016583 Anus disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000009531 Fissure in Ano Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 239000009223 Psyllium Substances 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 235000021282 Sterculia Nutrition 0.000 claims description 2
- 240000001058 Sterculia urens Species 0.000 claims description 2
- 206010046814 Uterine prolapse Diseases 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 229940069428 antacid Drugs 0.000 claims description 2
- 239000003159 antacid agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 229940069978 calcium supplement Drugs 0.000 claims description 2
- 239000007894 caplet Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229960004126 codeine Drugs 0.000 claims description 2
- 229940124579 cold medicine Drugs 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 208000014617 hemorrhoid Diseases 0.000 claims description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 208000003532 hypothyroidism Diseases 0.000 claims description 2
- 230000002989 hypothyroidism Effects 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 235000012245 magnesium oxide Nutrition 0.000 claims description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 229940095060 magnesium tartrate Drugs 0.000 claims description 2
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 229940127240 opiate Drugs 0.000 claims description 2
- 229940124583 pain medication Drugs 0.000 claims description 2
- 208000013823 pelvic organ prolapse Diseases 0.000 claims description 2
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 claims description 2
- 239000001472 potassium tartrate Substances 0.000 claims description 2
- 229940111695 potassium tartrate Drugs 0.000 claims description 2
- 235000011005 potassium tartrates Nutrition 0.000 claims description 2
- 230000035935 pregnancy Effects 0.000 claims description 2
- 229940070687 psyllium Drugs 0.000 claims description 2
- 201000010727 rectal prolapse Diseases 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 239000001433 sodium tartrate Substances 0.000 claims description 2
- 229960002167 sodium tartrate Drugs 0.000 claims description 2
- 235000011004 sodium tartrates Nutrition 0.000 claims description 2
- 229940059107 sterculia Drugs 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 239000003204 tranquilizing agent Substances 0.000 claims description 2
- 230000002936 tranquilizing effect Effects 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 238000010792 warming Methods 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 2
- 235000019800 disodium phosphate Nutrition 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 description 44
- 229940111504 visicol Drugs 0.000 description 33
- 238000002052 colonoscopy Methods 0.000 description 16
- 238000012800 visualization Methods 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 14
- 239000008108 microcrystalline cellulose Substances 0.000 description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 14
- 210000001815 ascending colon Anatomy 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000035568 catharsis Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000012943 hotmelt Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 238000013031 physical testing Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 239000008142 bulk forming laxative Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000009478 high shear granulation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 2
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229940079357 bulk-forming laxatives Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000008144 emollient laxative Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940031958 magnesium carbonate hydroxide Drugs 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910001479 sodium magnesium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002609 virtual colonoscopy Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Definitions
- This invention relates to colonic purgative formulations in solid dosage form and their use.
- the formulation contains at least one purgative and at least one soluble binder, which significantly improves the visualization of the colon and patient tolerance.
- the formulation is free of insoluble binder or only contains levels of insoluble binder that do not impede the visualization of the colon.
- the binder may be nonfermentable in certain embodiments of the invention.
- BACKGROUND OF THE INVENTION It is desirable to identify compounds that sufficiently cleanse the colon, but do not cause adverse side effects. It is also desirable to identify compounds that are used to treat constipation and promote fecal elimination, for instance, but that do not produce uncomfortable or embarrassing side effects such as gas. Additionally, completely clearing the bowel of fecal debris is a necessary prerequisite before a variety of diagnostic and surgical procedures. Cleansing is important, for instance, in order to sufficiently view the gross or microscopic appearance of the colon during colonoscopy. However, the cleansing procedure must also be tolerable to patients so that they are fully compliant with the cleansing process.
- MCC microcrystalline cellulose
- Figure 1 a purified form of cellulose, is used as a binder in the tablet formulation and is not soluble in the alimentary fluid. Retained MCC can be removed by suctioning or irrigation, so that the colon can be adequately visualized.
- these processes may prolong colonoscopy procedure time (Rex et al. (2002) Aliment Pharmacol. Ther. 16:937-944; Balaban et al. (2003) y4/77. J. Gastroenterol.
- the present invention relates to solid dosage form colonic purgative formulations and methods of their use.
- the solid dosage form colonic purgative formulation comprises at least one soluble binder and at least one purgative.
- the binder is nonfermentable.
- the formulation is free of insoluble binder or only contains levels of insoluble binder that do not impede the visualization of the colon.
- the at least one purgative may be an osmotic, non-osmotic, or bulk- forming purgative.
- the at least one purgative is an osmotic purgative chosen from sodium phosphate, magnesium phosphate, or a salt thereof.
- the sodium phosphate salt may be, for example, monobasic sodium phosphate, dibasic sodium phosphate, or tribasic sodium phosphate.
- the at least one purgative is a non-osmotic purgative chosen from bisacodyl or picosulfate, for example. [01 ⁇
- the colonic purgative formulation comprises at least one non-osmotic purgative and at least one osmotic purgative.
- the solid dosage form comprises polyethylene glycol as a soluble, nonfermentable binder.
- the formulation of the invention may also comprise optional components to improve dosage form characteristics. 'In one embodiment of the invention, the formulation comprises a lubricant, such as magnesium stearate, to improve the manufacturing process.
- the formulation of the invention is a dual function composition.
- the present invention encompasses methods of treating gastrointestinal disorders, such as constipation, by providing lower doses of the colonic purgative compositions of the invention as a laxative.
- the present invention also encompasses methods of complete purgation in order to prepare the colon for a colonoscopy or surgical procedure, by providing higher doses of the compositions of the invention as a complete purgative. Further, the present invention encompasses methods of maintaining the elimination or promoting the elimination of feces from the bowel by providing a colonic purgative composition of the invention.
- purgative refers to any substance that promotes defecation.
- purgative encompasses a range of cathartic effects.
- purgative encompasses mild catharsis, producing laxation ("partial purgation"), as well as stronger catharsis, providing complete or near-complete emptying of the large bowel (“complete purgation").
- partial purgation producing laxation
- complete purgation providing complete or near-complete emptying of the large bowel
- the term refers to a softening or loosening of the feces or laxation. Unless modified by "partial” or “complete,” purgative or purgation encompasses the full range of purgative processes, including both complete purgation and laxation (“partial purgation”). .
- the term “osmotic” may refer to the ability of a substance to draw water into the intestines.
- Fermentable refers to any substance that can be anaerobically catabolized to simpler compounds, usually by bacteria and/or yeast. There are many types of fermentation, differing in the waste products formed and the fermentable substance. Fermentable substances include, but are not limited to, sugars, sugar-alcohols, polysaccharides, lactose, sorbitol, and mannitol. A fermentable substance releases explosive gases upon fermentation. The compound mannitol, for instance, can be fermented by bacteria that are typically resident in the colon of most humans and other mammals, during which hydrogen gas is released. The term “nonfermentable” refers to a substance that is not fermentable.
- soluble or “water soluble” refers to an aqueous solubility that is higher than 1/10,000 (mg/ml).
- the solubility of a substance, or solute is the maximum mass of that substance that can be dissolved completely in a specified mass of the solvent, such as water.
- "Practically insoluble” or “insoluble,” on the other hand, refers to an aqueous solubility that is 1/10,000 (mg/ml) or less.
- Water soluble or soluble substances include, for example, polyethylene glycol.
- binding refers to any substance that exerts a physicochemical attractive force between molecules, and hence may be used in formulation of a dosage form.
- the binder may be mixed with other components of the composition, so that it is distributed uniformly throughout the dosage form.
- the binder may also provide a matrix upon which any additional components can associate.
- the binder is soluble and nonfermentable.
- Soluble and nonfermentable binders suitable for use in the invention include, but are not limited to, polyethylene glycol (PEG).
- PEG polyethylene glycol
- salts according to the present invention may be used in a variety of forms, for example anhydrous or a hydrated crystalline form. The salts may also be those that are physiologically tolerated by a patient.
- binders used in solid dosage formulations are insoluble. Applicants discovered that insoluble binders, such as microcrystalline cellulose (MCC), are retained in the colon, hamper visualization of the colon, and prolong colonoscopy procedure time ( Figure 1). Commonly used soluble binders, however, including sugars, sugar-alcohols, and polysaccharides, can be fermented by the intestinal flora. The formation of explosive gases during the fermentation process is an undesirable property during certain surgical and diagnostic procedures involving the colon, such as during a colonoscopy using equipment that may produce a spark. In some documented cases, the presence of these gases during colon electrosurgery has led to explosion (DeWilt et al. (1996) J. R. Coll.
- the solid dosage form colonic purgative formulation comprises at least one soluble, nonfermentable binder and at least one purgative.
- any soluble binder may be used in the composition. In these instances, it is not necessary that the binder or other ingredients be nonfermentable. Soluble, nonfermentable binders may, however, be used in compositions to prepare the colon for procedures that cannot produce a spark.
- Binders and Purgatives Any binder that is soluble, or soluble and nonfermentable, may be used in the present invention. However, binders that are fermentable, like any other fermentable ingredient, should only be used in embodiments where a spark would not be produced in the colon.
- a soluble, nonfermentable binder that may be used in the formulations of the invention includes, but is not limited to, polyethylene glycol (PEG). Applicants discovered that a purgative composition containing the soluble, nonfermentable binder PEG, leaves little or no residue after use for bowel preparation, thereby increasing visualization of the colon ( Figure 2).
- PEG is represented by the structural formula: HOCH 2 (CH 2 OCH 2 ) m CH 2 OH, wherein m represents the average number of oxyethylene groups.
- Any PEG polymer may be employed in the compositions contemplated herein.
- the PEG polymers are solid at room temperature (i.e., 25°C) and/or soluble in (or miscible with) water at room temperature.
- the average molecular weight of the PEG polymer is at least 200, at least 400, at least 600, at least 1 ,000, at least 1540, at least 3000, at least 4,000, or at least 8,000.
- the average molecular weight of the PEG polymer is from 7,000 to 9,000.
- the amount of soluble and/or non-fermentable binder may vary depending on the desired characteristics of the solid dosage form and can be determined by one of ordinary skill in the art.
- a PEG binder comprises 5-20%, in another embodiment 7.5-15%, and in an additional embodiment 10% by weight.
- the composition of the invention is free of insoluble binder or only contains levels of insoluble binder that do not impede the visualization of the colon.
- Various purgatives are available commercially, and any available form of the material can be used in the practice of this invention.
- Purgatives that may be used in the invention include, but are not limited to, non-osmotic, osmotic, and bulk- forming purgatives.
- the invention may contain one purgative, more than one purgative from the same category, or more than one purgative from different categories may be used. Many purgatives may have more than one role or function, or may be classified in more than one group. Such classifications are descriptive only, and not intended to limit any use of a particular purgative.
- at least one osmotic purgative is used in the formulation of the invention. Osmotic purgatives act by increasing intestinal osmotic pressure thereby promoting retention of fluid within the bowel.
- Osmotic purgatives that may be included in the composition include salts, for example, magnesium citrate, magnesium chloride, magnesium hydroxide, magnesium phosphate, magnesium sulfate, magnesium tartrate, sodium phosphate, sodium tartrate, sodium sulfate, potassium tartrate, magnesium oxide, sodium sulfate, or salts thereof.
- Other examples of osmotic purgatives include glycerin, sorbitol, mannitol, lactitol, alcohol sugars, L-sugars, polyethylene glycol, and lactulose.
- purgatives that are fermentable should only be used in embodiments where a spark would not be produced in the colon.
- the at least one purgative is sodium phosphate or a salt thereof. In an additional embodiment of the invention, the at least one purgative is monobasic sodium phosphate, dibasic sodium phosphate, or tribasic sodium phosphate.
- Salts according to the present invention may be used in a variety of forms, for example anhydrous or a hydrated form. It is also contemplated that a change in the form of a salt may increase or decrease its molecular weight. To account for any change in molecular weight, components of the purgative formulation and/or amounts of the purgative salts may be adjusted according to the knowledge of the person of ordinary skill in the art.
- the formulation of the invention comprises at least one non-osmotic purgative.
- Non-osmotic purgatives include prokinetic laxatives that stimulate the motility of the gastrointestinal tract, as well as stimulant laxatives that act by directly stimulating nerve endings in the colonic mucosa.
- Emollient laxatives and mucosal protectants may also be used in the invention.
- non-osmotic purgatives examples include, but are not limited to, mineral oil, aloe, bisacodyl, sodium picosulfate, casanthranol, cascara, castor oil, danthron, dehydrocholic acid, phenolphthalein, sennosides, docusate, bethanachol, colchicines, misoprostol, cisapride, norcisapride, paraffin, rhein, and tegaserod.
- the colonic purgative composition contains at least one osmotic purgative and at least one non-osmotic purgative.
- the colonic purgative formulations of the invention may also comprise at least one bulk-forming purgative.
- Bulk-forming purgatives cause retention of fluid and an increase in fecal mass, resulting in stimulation of peristalsis.
- Bulk-forming laxatives may include various natural and semisynthetic polysaccharides, cellulose derivatives, or other substances that dissolve or swell in water to form an emollient gel or viscous solution that serves to maintain the feces soft and hydrated.
- Additional optional components may be included in the formulations of this invention to, for example, enhance the characteristics of the solid dosage form, maintain the integrity of particles of the active ingredient during the formulation process, and/or enhance the safety of the formulation. Any additional components may be compatible with the other ingredients in the formulations of the invention, in particular the active ingredients, and may not adversely affect the osmolarity of the formulations.
- Additional optional ingredients that may be used in the formulations of the invention include, for example, coatings, diluents, binders, giidants, lubricants, colors, disintegrants, flavors, sweeteners, polymers or waxes.
- Lubricants for example, may be included in the formulations of the invention. Such lubricants include, but are not limited to, magnesium stearate, potassium stearate, talc, stearic acid, sodium lauryl sulphate, and paraffin.
- the colonic purgative formulation further comprises magnesium stearate-. Lubricants serve to facilitate the manufacturing of a solid • dosage form.
- Additional suitable ingredients also include, but are not limited to, carriers, such as sodium citrate and dicalcium phosphate; fillers or extenders, such as stearates, silicas, gypsum, starches, lactose, sucrose, glucose, mannitol, talc, and silicic acid; binders, such as hydroxypropyl methylcellulose, hydroxymethyl-cellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; humectants, such as glycerol; disintegrating agents, such as agar, calcium carbonate, potato and tapioca starch, alginic acid, certain silicates, colloidal silicon dioxide, sodium starch glycolate, crospovidone, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as cetyl alcohol and glycerol monostearate; absorbents, such as
- an additional component in the formulations of the invention may function to maintain the electrolyte balance in a patient.
- formulations of the invention may further comprise calcium, phosphate, potassium, magnesium, other anions, or salts thereof, which may normally be lost in diarrhea fluid.
- Acidic or basic compounds may also be optionally added to the composition to adjust the pH of the compound or to alter the disintegration characteristics. Acidic or basic compounds that may be included in the formulations of the invention include, but are not limited to, sodium carbonate, sodium bicarbonate, sodium phosphate, calcium carbonate, magnesium hydroxide, potassium hydroxide, magnesium carbonate, and aluminum hydroxide.
- the present invention also encompasses methods of using the colonic purgative formulations.
- the colonic purgative formulations of the invention produce a broad range of activities, depending on the dosage administered.
- the present invention encompasses methods of purging the colon comprising administering to at least one patient a colonic purgative formulation and allowing said formulation to purge the colon.
- the formulations of the invention may also be used at lower doses in order to regulate, soften or loosen the stool.
- the present invention also encompasses methods of maintaining the elimination or increasing the elimination of feces in the bowel, comprising administering to at least one patient a colonic purgative formulation and promoting the elimination of feces in the bowel.
- the colonic purgative formulations of the invention may also be used to treat a patient with constipation.
- the constipation may be caused by a variety of factors including, but not limited to at least one of travel; change in daily routine; lack of exercise; immobility caused by injury, illness, or aging; dehydration; irritable bowel syndrome; pregnancy; diabetes; hypothyroidism; hypercalcemia; cancer of the colon or rectum; uterine prolapse; vaginal vault prolapse; rectal prolapse; scarring from surgery; injury of the colon or rectum; Parkinson's disease; multiple sclerosis; stroke; hemorrhoid or anal fissures; delaying bowel movements; anxiety; depression; eating disorders; and obsessive- compulsive disorder.
- the constipation may also be idiopathic, i.e. of unknown causation.
- the composition of the invention is used to treat a patient suffering from, or susceptible to, constipation due to administration of a medication that causes constipation.
- a medication that may cause constipation includes, but is not limited to antacids that contain aluminum; antidepressants; blood pressure medications; calcium channel blockers; calcium supplements; chemotherapy medications; cold medicines; antihistamines; diuretics; iron supplements; medications for Parkinson's disease; lipid-lowering agents; pain medications; opiates; codeine; and tranquilizers.
- the appropriate dosage of the colonic purgative compositions may vary depending on the individual being treated and the purpose. For example, the age, body weight, and medical history of the individual patient may affect the therapeutic efficacy of the therapy. Further, a lower dosage of the composition may be needed to produce a mild catharsis, while complete purgation may require a higher dose. A competent physician can consider these factors and adjust the dosing regimen to ensure the dose is achieving the desired therapeutic outcome without undue experimentation. It is also noted that the clinician and/or treating physician will know how and when to interrupt, adjust, and/or terminate therapy in conjunction with individual patient response. Dosages also depend on the strength of the particular purgative(s) chosen for the formulation.
- the total dosage is administered in at least one application period. In an additional embodiment of the invention, the total dosage is administered in two or more separate application periods, or separate doses.
- the dose of the colonic purgative formulations may vary. For example, a lower dose of a colonic purgative formulation of the invention may be needed to produce a mild catharsis, while complete purgation may require a higher dose.
- a total daily dosage used for mild catharsis, for example, can range from 1 g to 30 g of a purgative.
- a total daily dosage of a purgative, such as sodium phosphate, in formulations of the present invention ranges from 1 to 30 g, 2 to 25 g, 3 to 20 g, 4 to 18 g, 5 to 16 g, 6 to 14 g, or 8 to 12 g.
- a total daily dosage may be formulated to contain 1 , 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, or 30 g of a purgative, such as sodium phosphate. Additional doses of the colonic purgative formulation may be necessary to produce the desired therapeutic effect.
- the total daily dosage is administered every 24 hours until the desired therapeutic effects are reached.
- a higher dose of a colonic purgative formulation of the invention may be needed to produce a complete purgation of the colon.
- a total dosage used for complete purgation can range from 20 g to 100 g of a purgative, optionally provided over a period of time of up to 24 hours.
- a total daily dosage of a purgative, such as sodium phosphate in formulations of the present invention may range from 20 to 100 g, 30 to 90 g, 40 to 80 g, or 50 to 70 g.
- a dose may be formulated to contain 20, 30, 40, 50, 60, 70, 80, 90, or 100 g of a purgative, such as sodium phosphate.
- the total daily dosage may be separated into divided doses.
- the total daily dosage is divided into two doses, separated by a period of up to 24 hours.
- a total daily dosage of 60 g of a purgative, such as sodium phosphate may be divided into two doses of 30 g each.
- One dose of 30 g may be administered in the evening before a colon procedure, while the second dose of 30 g may be administered in the morning, 3 to 5 hours before the colon procedure.
- the total daily dose is divided into three, four, or more doses.
- the addition of one or more purgatives to the composition may lower the amount of active ingredient in each dose, the number of doses, the administration time, and/or the number of tablets administered in a dose.
- the colonic purgative formulation is in an easily administered, solid dosage form. Solid dosage forms include, for example, a tablet, capsule, or caplet. The dosage form may be coated or encapsulated.
- the colonic purgative formulation is in the form of a tablet. The number of tablets administered in a dose may vary depending on the desired effect and on the amount of active ingredient in each solid dosage form.
- a colonic purgative composition of the invention may be part of a kit.
- the kit further comprises materials to assist in the administration of the composition, for instance a cup.
- the kit further comprises compositions that assist in laxation or complete purgation. Additional compositions that may be included in a kit with the colonic purgative compositions of the invention include, but are not limited to, at least one non-osmotic purgative, osmotic purgative, and/or bulk-forming laxative.
- the kit comprises a colonic purgative composition of the invention and a composition containing bisacodyl.
- a colonic purgative composition of the invention may be administered by various routes.
- the purgative composition is administered orally.
- the purgative composition is administered through a tube, for instance a feeding tube or nasogastric tube.
- the colonic purgative formulations of the invention may be manufactured in a variety of ways.
- the formulations may be produced using a direct-compression or hot-melt process.
- a process of producing a colonic purgative formulation comprises mixing the components, warming the mixture to the melting point of the polyethylene glycol, and compressing the mixture into tablets.
- the ingredients may be mixed in a high-shear mixer equipped with a jacketed mixing bowl.
- the blend may be warmed up to the melting point of PEG during mixing and cooling down when the end-point is reached.
- the blend may be cooled down overnight, milled, lubricated, and compressed into tablets.
- One of ordinary skill in the art will recognize methods of varying the manufacturing process to optimize the dosage form or increase the product amount for large scale manufacturing.
- Example 1 Preparation and use of colonic purgative formulations containing an insoluble binder [059] Two colonic purgative formulations, comprising the components set forth in Table 2, were produced by milling and blending, followed by direct compression.
- Table 2 Prior Art Colonic Purgative Compositions Containing an Insoluble Binder
- each Diacol ® tablet (InKine Pharmaceutical Company, Blue Bell, PA) was 2000.0 mg, which was consistently achieved by the manufacturing process.
- the target weight of each Visicol ® tablet (InKine Pharmaceutical Company, Blue Bell, PA) was 1764.8.0 mg, which was consistently achieved by the manufacturing process. Physical testing of both formulations revealed that the tablets exhibited an appropriate strength, hardness, and disintegration time.
- Visicol ® tablets were administered to humans in two, twenty tablet doses. One dose was administered the night before the colonoscopy procedure and the second dose was administered in the morning, 3 to 5 hours before the procedure. Colonoscopy revealed the presence of the binder, MCC, in the colon of patients.
- Example 2 Preparation of a colonic purgative formulation containing a soluble, nonfermentable binder
- a colonic purgative formulation comprising the components set forth in Table 3, was produced using a hot melt process via high-shear granulation followed by milling, lubrication, and compression.
- Table 3 Colonic Purgative Composition Containing a Soluble, Nonfermentable Binder
- sodium phosphate monobasic monohydrate (295.9 kg) was passed through a sieve equipped with a 10 mesh stainless steel screen.
- Sodium phosphate dibasic anhydrous (106.9 kg) and polyethylene glycol 8000 (45.0 kg) were each passed through a sieve equipped with a 20 mesh stainless steel screen.
- the sieved sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, and polyethylene glycol 8000 were loaded into a 250 L bin and blended for 23 minutes ⁇ 60 seconds at 12 rpm in a bin blender.
- the blended mixture was then transferred into suitable double poly-lined containers and milled through a cone mill, equipped with a stainless steel screen, at an impeller speed of 1400-1500 rpm.
- the milled mixture was then transferred back to the bin blender and further blended for 45 minutes ⁇ 60 seconds at 12 rpm.
- the materials were discharged into double poly-lined containers and divided into three sections.
- the lower jacket temperature on a mixer was set to 59°C, the upper jacket was turned on, and the heating water began circulating through the jacketed mixing bowl.
- the impeller speed was set at 30 rpm (with the granulator not running).
- the lower jacket temperature was then set to 66°C and the impeller speed at 50 rpm.
- the product temperature reached 40°C- 41 °C, the impeller speed was increased to 100 rpm.
- the granulator was set to speed 1 (slow) and the lower jacket temperature was set to 58°C.
- the granulation process was stopped.
- the lower jacket temperature was reduced to 20°C, the upper jacket was turned off, and the impeller speed was decreased to 10 rpm.
- the mixture was cooled until the product temperature reached 52°C.
- the granulation was then discharged into double poly-lined containers and stored in a closed, container at room temperature overnight. The process detailed above was repeated for divided sections two and three of the blended materials. [065] The next day, the temperature of the granulation was checked to ensure that it was less than 30°C.
- the granulation was then milled through the cone mill, equipped with a stainless steel screen, at an impeller speed of 1400-1500 rpm.
- the milled granulation was loaded into a 1200 L bin and blended for 23 minutes ⁇ 30 seconds at 12 rpm in a bin blender.
- Magnesium stearate (2.26 kg) was passed through a 30 mesh stainless steel hand screen and then added to the milled granulation in the 1200 L bin.
- the magnesium stearate was blended with the milled granulation for 10 minutes ⁇ 30 seconds at 12 rpm in the bin blender.
- the blended mixture was then compressed into tablets using a tablet press and dedusted using a tablet deduster.
- the target weight of each tablet was 1676.0 mg, which was consistently achieved by the manufacturing process. Physical testing of the tablet revealed that the tablet formulation exhibited an appropriate strength, hardness, and disintegration time. Surprisingly, the INKP-102 tablet could be formulated successfully as a smaller tablet than the prior art compositions, Diacol ® and Visicol ® , even though the same amount of active ingredient (1102 mg sodium phosphate monobasic monohydrate and 398 mg sodium phosphate dibasic anhydrous) was used in each of the three compositions (Table 4). This surprising result is very beneficial as the improved formulation is more tolerable to patients, allowing them to more easily administer the active ingredients.
- the disintegration time of the INKP-102 tablet is decreased, resulting in a more rapid response to the colonic purgative composition. Additionally, this decrease in disintegration time cannot be accounted for merely by the reduced size of the tablet, as there is a steeper decline in disintegration time compared to tablet size. This more rapid response would be especially beneficial whether a patient administered the composition of the invention to treat constipation or to completely purge the colon.
- Table 4 Colonic Purgative Composition Containing a Soluble, Nonfermentable Binder
- Example 3 Preparation of a colonic purgative formulation containing a soluble, nonfermentable binder
- a colonic purgative formulation comprising the components set forth in Table 5, is produced using a hot melt process via high-shear granulation followed by milling, lubrication, and compression.
- Table 5 Colonic Purgative Composition Containing a Soluble, Nonfermentable Binder
- Example 4 A colonic purgative composition to purge the colon [069] A patient undergoing a surgical or diagnostic procedure involving the colon is administered 40 tablets of a colonic purgative composition, such as the composition described in Example 2 or 3. The evening before the surgical or diagnostic procedure, 3 tablets are taken with at least 8 ounces of clear liquids every
- a colonic purgative composition containing an osmotic and non-osmotic purgative to purge the colon may also be administered in a single application or dose.
- a patient undergoing a surgical or diagnostic procedure involving the colon is administered 20 tablets of a colonic purgative composition, such as the composition described in Example 3.
- a colonic purgative composition such as the composition described in Example 3.
- 3 tablets are taken with at least 8 ounces of clear liquids every 15 minutes (the last dose will be 2 tablets) for a total of 20 tablets. It is expected that the results of such treatment will provide an adequately cleansed bowel, demonstrate little or no residue that impairs visual inspection of the colon, and is tolerable to the patient both in its palatability and side effect profile. Further, it is expected that no morning dose will be required to obtain quality cleansing of the bowel.
- Example 6 A colonic purgative composition to treat constipation [071]
- a patient with constipation is treated with a colonic purgative composition, such as the composition described in Example 2 or 3.
- the composition is administered in a total daily dose of 3 to 18 g, which is given over a period of up to 30 minutes. The dose may be repeated daily. It is expected that the results of such treatment will facilitate the passage of feces and promote elimination, by loosening or softening of the stool and/or the promotion of peristalsis due to increased amounts of water in the colon. It is beneficial to be able to use the same dual function composition for complete purgation and laxation.
- Example 7 Colon cleansing efficacy of INKP-102
- the primary objective of this study was to compare, by direct visualization, the colon cleansing efficacy of a composition of one embodiment of the invention (See Table 3; hereinafter "INKP-102") versus the marketed Visicol ® tablets (See Table 2; InKine Pharmaceutical Company, Blue Bell, PA) in patients undergoing colonoscopy.
- INKP-102 The components of INKP-102 (1676 mg tablet) were as set forth in Table 3 above.
- Visicol ® tablets were comprised of the same amount of active ingredient as INKP-102 (1102 mg sodium phosphate monobasic monohydrate and 398 mg sodium phosphate dibasic anhydrous).
- the inert ingredients of Visicol ® tablets included MCC, colloidal silicon dioxide, and magnesium stearate, as set forth in Table 2 above.
- the primary objective of the study was to evaluate the colon cleansing efficacy of INKP-102 compared with Visicol ® tablets in patients undergoing colonoscopy.
- endoscopists assessed the patients' colons overall, and also specifically assessed patients' ascending colons, where MCC residue especially impairs visualization of the colon.
- Tables 7a and 7b display the results of endoscopist assessment of "colonic contents” overall and in the ascending colon, respectively, in the "All- Assessed” population.
- Comparison of Visicol ® versus INKP-102 treatments revealed that mean overall colonic contents scores were significantly better with INKP-102 dosages (Arms B, C, and E) than with Visicol ® (P ⁇ 0.05; Arm A).
- assessment of colonic contents in the ascending colon revealed that INKP-102 treatment with Arms B, C, and E resulted in significantly better mean colonic contents scores than with Visicol ® treatment (P ⁇ 0.05; Arm A).
- the dosing regimens of treatment Arms D and F only involve an evening dose, they may be more preferable to patients who do not want to get up early before a procedure to complete a dosing regimen and more preferable to anesthesiologists who require that the patient receive nothing by mouth on the morning of the procedure.
- the dosing regimen of treatment Arm D only involves an evening dose, it may be more preferable to patients who do not want to get up early before a procedure to complete a dosing regimen and more preferable to anesthesiologists who require that the patient receive nothing by mouth on the morning of the procedure.
- Table 9a Colonic Cleansing (Colonic Contents) Responder Rates in the "All- Assessed" Population
- inorganic phosphorus exhibited a significant, after-treatment difference between the INKP-102 and Visicol ® treatment arms. Increases from baseline in inorganic phosphorus were anticipated and occurred with a mean increase of 88% over baseline levels in all patients, regardless of treatment arm. These increases in inorganic phosphorus levels were significantly higher among Arm A (Visicol ® Tablets) than in patients in treatment arms D, E, F, and G (INKP-102; P ⁇ 0.0170). The inorganic form of phosphate in the circulating plasma is excreted almost entirely by the kidneys and therefore some patients, such as those with renal disease, may have difficulty excreting a large phosphate load.
- INKP-102 beneficially reduces the burden on the kidneys during sodium phosphate treatment. This effect may be attributable to the reduced sodium phosphate doses in Arms D, E, F, and G. As described in several efficacy analyses above, however, INKP-102 more effectively cleanses the colon than a larger sodium phosphate dose of Visicol ® , while at the same time reducing the increase in inorganic phosphorous normally observed with Visicol ® administration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020117019045A KR101268559B1 (en) | 2003-11-19 | 2004-11-17 | Colonic purgative composition with soluble binding agent |
CN2004800407012A CN101087593B (en) | 2003-11-19 | 2004-11-17 | Colonic purgative composition with soluble binding agent |
KR1020137007695A KR101495690B1 (en) | 2003-11-19 | 2004-11-17 | Colonic purgative composition with soluble binding agent |
ES04819530.9T ES2584866T3 (en) | 2003-11-19 | 2004-11-17 | Purgative composition for the colon with soluble binding agent |
JP2006541302A JP5329042B2 (en) | 2003-11-19 | 2004-11-17 | Colonic laxative composition comprising a soluble binder |
KR1020127003801A KR101323628B1 (en) | 2003-11-19 | 2004-11-17 | Colonic purgative composition with soluble binding agent |
BRPI0416702A BRPI0416702B8 (en) | 2003-11-19 | 2004-11-17 | colonic purgative formulation in a solid dosage form for oral administration, and kit |
CA2546637A CA2546637C (en) | 2003-11-19 | 2004-11-17 | Colonic purgative composition with soluble binding agent |
BR122014001142A BR122014001142B8 (en) | 2003-11-19 | 2004-11-17 | process of producing a colonic purgative tablet formulation for oral administration |
EP04819530.9A EP1682098B1 (en) | 2003-11-19 | 2004-11-17 | Colonic purgative composition with soluble binding agent |
AU2004292428A AU2004292428B2 (en) | 2003-11-19 | 2004-11-17 | Colonic purgative composition with soluble binding agent |
AU2011202346A AU2011202346B2 (en) | 2003-11-19 | 2011-05-20 | Colonic purgative composition with soluble binding agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52314203P | 2003-11-19 | 2003-11-19 | |
US60/523,142 | 2003-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005051361A1 true WO2005051361A1 (en) | 2005-06-09 |
Family
ID=34632758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/038220 WO2005051361A1 (en) | 2003-11-19 | 2004-11-17 | Colonic purgative composition with soluble binding agent |
Country Status (12)
Country | Link |
---|---|
US (3) | US7687075B2 (en) |
EP (2) | EP1682098B1 (en) |
JP (3) | JP5329042B2 (en) |
KR (4) | KR101495690B1 (en) |
CN (2) | CN101087593B (en) |
AR (1) | AR046651A1 (en) |
AU (2) | AU2004292428B2 (en) |
BR (2) | BRPI0416702B8 (en) |
CA (2) | CA2546637C (en) |
ES (1) | ES2584866T3 (en) |
PL (1) | PL1682098T3 (en) |
WO (1) | WO2005051361A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007131687A1 (en) * | 2006-05-12 | 2007-11-22 | Madaus, S.A. | Pharmaceutical composition comprising plantago ovata and its use in the treatment of parkinson's disease |
EP1877039A1 (en) * | 2005-05-06 | 2008-01-16 | Salix Pharmaceuticals, Inc. | Polyethylene glycol colonic purgative composition |
EP2003966A2 (en) * | 2006-04-07 | 2008-12-24 | Sunten Phytotech Co., Ltd. | Anthracenedione compounds |
WO2009137672A1 (en) * | 2008-05-07 | 2009-11-12 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel disease by administering a bowel cleanser and an antibiotic |
US7658914B2 (en) | 2002-10-25 | 2010-02-09 | Norgine Bv | Colon cleansing compositions |
EP1742645B1 (en) * | 2004-04-23 | 2011-01-26 | Norgine BV | Compressed pharmaceutical compositions comprising peg and electrolytes |
EP2411022A1 (en) * | 2009-03-27 | 2012-02-01 | Salix Pharmaceuticals, Ltd. | Compositions for bowel preparation and methods of use thereof |
EP2476424A1 (en) * | 2009-08-31 | 2012-07-18 | Zeria Pharmaceutical Co., Ltd. | Orally administrable tablet for intestinal lavage |
US8507009B2 (en) | 2003-11-19 | 2013-08-13 | Salix Pharmaceuticals, Inc. | Colonic purgative composition with soluble binding agent |
EP2651415A1 (en) * | 2010-12-13 | 2013-10-23 | Thomas Julius Borody | Gastric and colonic formulations and methods for making and using them |
EP2997969A4 (en) * | 2013-05-17 | 2017-01-18 | Kyowa Chemical Industry Co., Ltd | Treatment agent and treatment method for intestinal examination or surgery |
CN107787223A (en) * | 2015-06-22 | 2018-03-09 | 西梯茜生命工学股份有限公司 | Cleaning intestinal tract purgatives composition |
US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090105537A1 (en) * | 2004-12-30 | 2009-04-23 | Daniel Gat | Device, System and Method for In-Vivo Examination |
AU2013202513B2 (en) * | 2005-05-06 | 2016-03-24 | Salix Pharmaceuticals, Inc. | Polyethylene glycol colonic purgative composition |
CN1748675A (en) * | 2005-07-11 | 2006-03-22 | 丛晓东 | Composition of rheinic acid compounds and preparing method and use for treating diabetes |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
DE102006017672B4 (en) * | 2006-04-12 | 2008-07-03 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Composition for use as a laxative |
DE102007023397B4 (en) * | 2007-05-02 | 2015-03-26 | Madaus Gmbh | New pharmaceutical composition for use as a laxative |
NZ580999A (en) * | 2007-05-17 | 2012-05-25 | David Lubowski | Combination laxative compositions comprising a colonic stimulant and a bulking laxative |
US20080287486A1 (en) * | 2007-05-17 | 2008-11-20 | Theravance, Inc. | Prokinetic agent for bowel preparation |
CN101450049A (en) * | 2007-12-07 | 2009-06-10 | 辉凌国际制药(瑞士)有限公司 | Pharmaceutical composition |
WO2010005965A1 (en) * | 2008-07-08 | 2010-01-14 | Aronchick Craig A | Colonic purgative formulations and methods of using the same |
KR101053731B1 (en) * | 2008-10-21 | 2011-08-02 | 이문성 | Method for preparing dissolution time-controlled enteric cleaner composition |
US20100178360A1 (en) * | 2009-01-13 | 2010-07-15 | Universite Libre De Bruxelles | Nutritive composition |
US8778306B2 (en) * | 2009-04-21 | 2014-07-15 | Dale R. Bachwich | Colon lavage system |
CN101874796A (en) * | 2009-04-29 | 2010-11-03 | 田普森 | Medical preparation for treating astriction and preparation method thereof |
RU2536691C2 (en) * | 2009-06-03 | 2014-12-27 | Апталис Фарма ЮЭс, Инк. | Colon cleansing l-sugar agent and using it |
EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | Methods for treating gastrointestinal disorders |
US20110021591A1 (en) * | 2009-07-21 | 2011-01-27 | Gordon Douglas J | Phenylbutazone carrier formulation showing increased bioactivity in animals |
US9040095B2 (en) * | 2009-10-14 | 2015-05-26 | Gi Innovations, Pllc | Colon cleansing of residual stool and secretions during colonoscopy |
NZ598716A (en) * | 2009-10-26 | 2014-08-29 | Borody Thomas J | Novel enteric combination therapy |
CN102283861A (en) * | 2010-06-17 | 2011-12-21 | 杭州赛利药物研究所有限公司 | Application of magnesium hydrate to pharmacy as well as magnesium hydrate preparation and preparation method thereof |
CA2825808C (en) | 2011-01-28 | 2020-09-01 | William A. Shaver | Method, composition and package for bowel cleansing |
TWI535461B (en) | 2011-03-11 | 2016-06-01 | 諾金私人有限公司 | Colon cleansing solutions,compositions for preparing the solutions,kits comprising the compositions or solutions,and methods for preparing the solutions |
US8778907B2 (en) * | 2011-04-27 | 2014-07-15 | Cumberland Pharmaceuticals | Lactulose for bowel evacuation |
CN102178694B (en) * | 2011-05-06 | 2013-03-20 | 四川健能制药有限公司 | Liquid preparation of sodium ascorbyl phosphate |
JP5842521B2 (en) * | 2011-09-30 | 2016-01-13 | ゼリア新薬工業株式会社 | Constipation medication |
BR112014009946A2 (en) * | 2011-10-27 | 2017-04-25 | Salix Pharmaceuticals Inc | "purgative composition, pharmaceutical composition or formulation and use thereof" |
RU2473330C1 (en) * | 2011-12-09 | 2013-01-27 | Александр Павлович Погромов | Medication for intestinal lavage |
PT2895163T (en) | 2012-09-11 | 2019-06-14 | Norgine Bv | Compositions comprising peg and ascorbate |
MX2015012109A (en) | 2013-03-15 | 2016-04-15 | Braintree Lab | Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof. |
CN103585173B (en) * | 2013-10-28 | 2016-06-29 | 王显著 | Sulfur acid sodium and can the pharmaceutical composition of sulphuric acid |
KR101659746B1 (en) | 2014-01-28 | 2016-09-26 | 주식회사한국파마 | Colonic purgative compositions comprising sulfate salts and a method for preparing the same |
KR20170007303A (en) | 2014-04-29 | 2017-01-18 | 코로나리콘셉츠 엘엘씨 | Foods, systems, methods, and kits for providing electrolyte replacement |
US10067103B2 (en) | 2015-03-02 | 2018-09-04 | Colonaryconcepts Llc | Compounds and methods for PEG metabolite and PEG breakdown product assays |
WO2017011430A1 (en) * | 2015-07-13 | 2017-01-19 | Halow George M | Bowel cleansing compositions and methods |
US20190000976A1 (en) * | 2016-01-28 | 2019-01-03 | Ctc Bio,Inc. | Purgative Composition |
JP2018131396A (en) * | 2017-02-14 | 2018-08-23 | 学校法人自治医科大学 | Oral intestinal cleanser and booster for large intestine capsule endoscope |
US10143656B1 (en) | 2017-08-04 | 2018-12-04 | Braintree Laboratories, Inc. | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
KR102005072B1 (en) * | 2017-12-15 | 2019-07-29 | 주식회사 씨티씨바이오 | Laxative composition for colon cleansing |
KR102111094B1 (en) | 2018-06-18 | 2020-05-14 | 주식회사 한국팜비오 | Oral solid formulation composition for purgative comprising sodium sulfate anhydrous, potassium sulfate, magnesium sulfate anhydrous and simethicone |
CN112386577B (en) * | 2019-08-16 | 2024-01-23 | 北京天衡药物研究院有限公司 | Composition for treating constipation |
CN112587498A (en) * | 2020-12-29 | 2021-04-02 | 哈尔滨瀚钧现代制药有限公司 | Docusate sodium danthron anthraquinone and preparation method thereof |
CN115040512B (en) * | 2022-07-28 | 2023-06-20 | 苏州中化药品工业有限公司 | Pharmaceutical composition and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3121663A (en) * | 1956-02-09 | 1964-02-18 | Plough Lab Inc | Carbon dioxide releasing laxative suppository |
US5616346A (en) * | 1993-05-18 | 1997-04-01 | Aronchick; Craig A. | Non-aqueous colonic purgative formulations |
US5710183A (en) * | 1995-07-14 | 1998-01-20 | Halow; George M. | Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent |
WO2002026222A2 (en) * | 2000-09-28 | 2002-04-04 | Braintree Laboratories, Inc. | Method of achieving overnight laxation and control of bowel function |
WO2003092589A2 (en) * | 2002-04-30 | 2003-11-13 | Braintree Laboratories, Inc. | Salt solution for colon cleansing |
WO2004006833A2 (en) * | 2002-07-15 | 2004-01-22 | Halow George M | Bowel cleansing composition |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3202578A (en) * | 1957-09-27 | 1965-08-24 | Elder Paul B Co | Polymeric laxative composition and method of using same |
GB1459488A (en) * | 1974-03-19 | 1976-12-22 | Wyeth John & Brother Ltd | Piperazinedione derivatives |
US4321263A (en) * | 1980-09-30 | 1982-03-23 | Rowell Laboratories, Inc. | Psyllium compositions |
US4812311A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
AU6196786A (en) | 1985-08-01 | 1987-03-05 | Braintree Laboratories Inc. | Low-sodium laxative and lavage formulation |
US4849227A (en) * | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
US4828842A (en) * | 1986-09-16 | 1989-05-09 | L. Perrigo Company | Water dispersible compound |
US4999200A (en) * | 1987-12-09 | 1991-03-12 | Marion Laboratories | Psyllium tablet composition, method of manufacture and method of use |
JPH0816061B2 (en) * | 1988-07-13 | 1996-02-21 | 森下ルセル株式会社 | Intestinal lavage fluid composition and intestinal lavage fluid |
US5294451A (en) * | 1991-03-29 | 1994-03-15 | Curtice-Burns, Inc. | Fat substitute compositions having reduced laxative effects |
US5397573A (en) * | 1993-06-04 | 1995-03-14 | The Procter & Gamble Company | Laxative compositions |
US5516524A (en) * | 1993-12-20 | 1996-05-14 | The Procter & Gamble Company | Laxative compositions containing bulk fiber |
US5498425A (en) * | 1995-03-17 | 1996-03-12 | Block Drug Company, Inc. | Phosphosoda buffered saline laxative |
FR2746643B1 (en) * | 1996-04-01 | 1998-06-12 | Techni Pharma | NOVEL LAXATIVE COMPOSITIONS AND THEIR MANUFACTURING PROCESS |
AU731016B2 (en) * | 1996-11-13 | 2001-03-22 | C.B. Fleet Company Incorporated | A coated sodium phosphate bowel cleanser |
US6162464A (en) * | 1997-03-31 | 2000-12-19 | Inkine Pharmaceutical, Inc. | Non-aqueous colonic purgative formulations |
US6048901A (en) * | 1999-04-20 | 2000-04-11 | Braintree Laboratories, Inc. | Method of reducing intestinal gas, cramping and anorectal irritation |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US20040071779A1 (en) | 2002-10-09 | 2004-04-15 | Keiser Dale Arthur | Gelled laxative compositions |
US7687075B2 (en) | 2003-11-19 | 2010-03-30 | Salix Pharmaceuticals, Ltd. | Colonic purgative composition with soluble binding agent |
-
2004
- 2004-11-16 US US10/988,693 patent/US7687075B2/en active Active
- 2004-11-17 EP EP04819530.9A patent/EP1682098B1/en active Active
- 2004-11-17 ES ES04819530.9T patent/ES2584866T3/en active Active
- 2004-11-17 JP JP2006541302A patent/JP5329042B2/en active Active
- 2004-11-17 CN CN2004800407012A patent/CN101087593B/en active Active
- 2004-11-17 KR KR1020137007695A patent/KR101495690B1/en active IP Right Grant
- 2004-11-17 KR KR1020127003801A patent/KR101323628B1/en active IP Right Grant
- 2004-11-17 KR KR1020117019045A patent/KR101268559B1/en active IP Right Grant
- 2004-11-17 AU AU2004292428A patent/AU2004292428B2/en not_active Ceased
- 2004-11-17 BR BRPI0416702A patent/BRPI0416702B8/en active IP Right Grant
- 2004-11-17 CA CA2546637A patent/CA2546637C/en active Active
- 2004-11-17 CN CN201210119344.5A patent/CN102648980B/en active Active
- 2004-11-17 KR KR1020067011762A patent/KR20060114342A/en not_active Application Discontinuation
- 2004-11-17 CA CA2814523A patent/CA2814523C/en active Active
- 2004-11-17 PL PL04819530.9T patent/PL1682098T3/en unknown
- 2004-11-17 EP EP10180972.1A patent/EP2308476B1/en active Active
- 2004-11-17 WO PCT/US2004/038220 patent/WO2005051361A1/en active Application Filing
- 2004-11-17 BR BR122014001142A patent/BR122014001142B8/en active IP Right Grant
- 2004-11-19 AR ARP040104289A patent/AR046651A1/en not_active Application Discontinuation
-
2008
- 2008-03-13 US US12/075,772 patent/US7718197B2/en active Active
-
2010
- 2010-01-20 US US12/690,384 patent/US8507009B2/en active Active
-
2011
- 2011-05-20 AU AU2011202346A patent/AU2011202346B2/en not_active Ceased
- 2011-06-14 JP JP2011132713A patent/JP5502807B2/en active Active
-
2014
- 2014-01-17 JP JP2014007066A patent/JP2014065746A/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3121663A (en) * | 1956-02-09 | 1964-02-18 | Plough Lab Inc | Carbon dioxide releasing laxative suppository |
US5616346A (en) * | 1993-05-18 | 1997-04-01 | Aronchick; Craig A. | Non-aqueous colonic purgative formulations |
US5710183A (en) * | 1995-07-14 | 1998-01-20 | Halow; George M. | Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent |
WO2002026222A2 (en) * | 2000-09-28 | 2002-04-04 | Braintree Laboratories, Inc. | Method of achieving overnight laxation and control of bowel function |
WO2003092589A2 (en) * | 2002-04-30 | 2003-11-13 | Braintree Laboratories, Inc. | Salt solution for colon cleansing |
WO2004006833A2 (en) * | 2002-07-15 | 2004-01-22 | Halow George M | Bowel cleansing composition |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658914B2 (en) | 2002-10-25 | 2010-02-09 | Norgine Bv | Colon cleansing compositions |
US8507009B2 (en) | 2003-11-19 | 2013-08-13 | Salix Pharmaceuticals, Inc. | Colonic purgative composition with soluble binding agent |
EP1742645B1 (en) * | 2004-04-23 | 2011-01-26 | Norgine BV | Compressed pharmaceutical compositions comprising peg and electrolytes |
EP1877039A4 (en) * | 2005-05-06 | 2010-08-18 | Salix Pharmaceuticals Inc | Polyethylene glycol colonic purgative composition |
EP1877039A1 (en) * | 2005-05-06 | 2008-01-16 | Salix Pharmaceuticals, Inc. | Polyethylene glycol colonic purgative composition |
EP2676667A1 (en) * | 2005-05-06 | 2013-12-25 | Salix Pharmaceuticals, Inc. | Polyethylene glycol colonic purgative composition |
EP2003966A4 (en) * | 2006-04-07 | 2010-07-07 | Sunten Phytotech Co Ltd | Anthracenedione compounds |
US8466202B2 (en) | 2006-04-07 | 2013-06-18 | Sunten Phytotech Co., Ltd. | Anthracenedione compounds |
EP2003966A2 (en) * | 2006-04-07 | 2008-12-24 | Sunten Phytotech Co., Ltd. | Anthracenedione compounds |
WO2007131687A1 (en) * | 2006-05-12 | 2007-11-22 | Madaus, S.A. | Pharmaceutical composition comprising plantago ovata and its use in the treatment of parkinson's disease |
ES2292345A1 (en) * | 2006-05-12 | 2008-03-01 | Madaus, S.A. | Pharmaceutical composition comprising plantago ovata and its use in the treatment of parkinson's disease |
WO2009137672A1 (en) * | 2008-05-07 | 2009-11-12 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel disease by administering a bowel cleanser and an antibiotic |
EP2411022A1 (en) * | 2009-03-27 | 2012-02-01 | Salix Pharmaceuticals, Ltd. | Compositions for bowel preparation and methods of use thereof |
EP2411022A4 (en) * | 2009-03-27 | 2012-10-17 | Salix Pharmaceuticals Ltd | Compositions for bowel preparation and methods of use thereof |
EP2476424A4 (en) * | 2009-08-31 | 2013-03-13 | Zeria Pharm Co Ltd | Orally administrable tablet for intestinal lavage |
US8454995B2 (en) | 2009-08-31 | 2013-06-04 | Zeria Pharmaceutical Co., Ltd. | Peroral tablet for bowel cleansing |
EP2476424A1 (en) * | 2009-08-31 | 2012-07-18 | Zeria Pharmaceutical Co., Ltd. | Orally administrable tablet for intestinal lavage |
EP2651415A1 (en) * | 2010-12-13 | 2013-10-23 | Thomas Julius Borody | Gastric and colonic formulations and methods for making and using them |
EP2651415A4 (en) * | 2010-12-13 | 2014-04-23 | Borody Thomas J | Gastric and colonic formulations and methods for making and using them |
AU2011342368B2 (en) * | 2010-12-13 | 2016-11-17 | Rite-Prep Pty Ltd | Gastric and colonic formulations and methods for making and using them |
US10092573B2 (en) | 2010-12-13 | 2018-10-09 | Salix Pharmaceuticals, Inc. | Gastric and colonic formulations and methods for making and using them |
US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
EP2997969A4 (en) * | 2013-05-17 | 2017-01-18 | Kyowa Chemical Industry Co., Ltd | Treatment agent and treatment method for intestinal examination or surgery |
CN107787223A (en) * | 2015-06-22 | 2018-03-09 | 西梯茜生命工学股份有限公司 | Cleaning intestinal tract purgatives composition |
EP3311814A4 (en) * | 2015-06-22 | 2019-02-27 | CTC Bio, Inc. | Purgative composition for cleansing intestinal tract |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7687075B2 (en) | Colonic purgative composition with soluble binding agent | |
JP5871830B2 (en) | Polyethylene glycol colon laxative composition | |
JP2007512336A5 (en) | ||
AU2015221520B2 (en) | Colonic purgative composition with soluble binding agent | |
AU2012202628B2 (en) | Colonic purgative composition with soluble binding agent | |
JP2726165B2 (en) | Shampoo composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006541302 Country of ref document: JP Ref document number: 2546637 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004819530 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004292428 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067011762 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2004292428 Country of ref document: AU Date of ref document: 20041117 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004292428 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480040701.2 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004819530 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067011762 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0416702 Country of ref document: BR Free format text: APRESENTE DOCUMENTOS COMPROBATORIOS QUE EXPLIQUEM A DIVERGENCIA NO NOME DE UM DOS INVENTORES QUE CONSTA NA PUBLICACAO INTERNACIONAL WO 2005/051361 DE 09/06/2005 "STEPHEN SKIENDZIELEWSKI" E O CONSTANTE DA PETICAO INICIAL NO 020060070989 DE 18/05/2006 "STEPHEN SKIEDZIELEWSKI". |
|
ENP | Entry into the national phase |
Ref document number: PI0416702 Country of ref document: BR Kind code of ref document: A2 Effective date: 20060518 |